Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients

Table 2 Univariate analysis of predictive variables associated with incidence probability of post-transplant cutaneous squamous cell carcinoma

Covariates	Hazard ratio (95%CI)	P value
Age	1.08 (1.07-1.09)	< 0.001
Female	0.310 (0.260-0.370)	< 0.001
HLA mismatch level	0.914 (0.870-0.960)	< 0.001
PRA against Class I antigens	0.994 (0.990-0.998)	0.006
PRA against Class II antigens	0.994 (0.989-0.999)	0.012
Race
White	1	-
Black	0.0390 (0.0221-0.068)	<0.001
Hispanic	0.178 (0.120-0.265)	<0.001
Other	0.108 (0.0512-0.226)	<0.001
Diagnosis
Dilated myopathy	1	-
Restrictive myopathy	1.38 (0.985-1.93)	0.061
Heart re-transplant	1.12 (0.807-1.55)	0.500
Coronary artery disease	1.49 (1.22-1.82)	< 0.001
Hypertrophic myopathy	0.923 (0.630-1.35)	0.681
Valvular heart disease	1.16 (0.842-1.59)	0.368
Congenital heart defect	0.393 (0.232-0.666)	0.001
Other	1.01 (0.695-1.47)	0.951
Donor cancer history
No	1	-
Yes	1.28 (0.883-1.84)	0.195
Unknown	0.997 (0.321-3.10)	0.997
Malignancy at listing
No	1	-
Yes	1.72 (1.43-2.09)	< 0.001
Unknown	0.983 (0.667-1.45)	0.930
Malignancy at transplant
No	1	0
Yes	2.55 (1.48-4.41)	0.001
Unknown	0.791 (0.528-1.18)	0.255
Donor skin cancer history
No	1	-
Yes	1.06 (0.265-4.24)	0.935
Unknown	0.631 (0.439-0.906)	0.013
Patient status at transplant
Status 1A	1	-
Status 1B	1.07 (0.950-1.20)	0.274
Status 2	0.983 (0.854-1.13)	0.805
Induction with thymoglobulin	1.05 (0.911-1.22)	0.481
Induction with ATGAM	0.980 (0.784-1.22)	0.857
Induction with OKT3	1.59 (1.27-2.01)	< 0.001
Induction with daclizumab	1.16 (0.995-1.36)	0.057
Induction with basiliximab	1.08 (0.927-1.26)	0.322
Induction with alemtuzumab	1.18 (0.773-1.80)	0.444

HLA: Human leukocyte antigen; PRA: Panel-reactive antibody; CI: Confidence interval.